Comparing the current results to its competitors, Halozyme Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 47.67 % year on year. The sales growth was above Halozyme Therapeutics Inc 's competitors' average revenue growth of 11.53 %, achieved in the same quarter.
Halozyme Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape for ENHANZE technology includes alternative approaches and emerging technologies such as Alteogen Inc.'s ALT-B4. Hylenex recombinant, the only FDA-approved recombinant human hyaluronidase, competes with Amphastar Pharmaceuticals, Inc.'s Amphadase®, a bovine hyaluronidase. In the U.S. testosterone replacement therapy market, competitors include AbbVie's Androgel® 1% and 1.62%, Perrigo's generic Androgel® Topical Gel 1.62%, Lilly's Axiron®, Endo, Inc.'s Testim® and Fortesta® (including the authorized generic), and oral formulations like Kyzatrex by Marius Pharmaceuticals, Inc. Competitors encompass specialty pharmaceutical companies, major brand name and generic manufacturers such as Teva, Viatris, Lilly, and Endo, as well as medical device companies including Scandinavian Health Ltd., Ypsomed AG, West Pharmaceutical, and Owen Mumford Ltd. Many competitors possess greater financial, commercial, research, development, marketing, and manufacturing resources.
Due to outstanding performance in Overall company, revenue grew by 47.67 % Halozyme Therapeutics Inc improved its market share, to approximately 5.75 %.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Adverum Biotechnologies Inc's business model is focused on developing gene therapies using its proprietary platform to deliver therapeutics for eye diseases.
Sources:
Halozyme Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Halozyme Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
